Growth charts for prepubertal children with chronic renal failure due to congenital renal disorders

Schaefer, Franz; Wingen, A.-M.; Hennicke, Mascha; Rigden, S. P. A.; Mehls, Otto

doi:10.1007/bf00866762

Cited by 65 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pediatric registry data has also shown increased mortality rates in children with poor growth (51–53). Longitudinal analysis of CKiD data will study the effects of declining kidney function on growth and evaluate the impact of growth failure on morbidity in children with kidney disease.…”

Section: Cardiovascular Disease Risk Factors In Children With Ckdmentioning

confidence: 99%

CKiD (CKD in Children) Prospective Cohort Study: A Review of Current Findings

Wong

Moxey-Mims

Jerry-Fluker

et al. 2012

American Journal of Kidney Diseases

231

152

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a life-long condition associated with substantial morbidity and premature death due to complications from progressive decline in kidney function. The incidence and prevalence of all stages of CKD in children continues to increase worldwide. Between 2000 and 2008, the kidney replacement therapy incidence rate among those 0–19 years of age rose 5.9% to 15 per million population, highlighting the importance of CKD research in children. Many comorbid conditions seen in adults with CKD, including cardiovascular disease and cognitive impairment, are also highly prevalent in children, implicitly demonstrating the crucial need for initiating therapy early to improve health outcomes in children with CKD. The CKiD (Chronic Kidney Disease in Children) study is a prospective cohort study of 586 children aged 1–16 years with an estimated glomerular filtration rate (eGFR) between 30 and 90 ml/min/1.73 m2. Since its inception, CKiD has identified risk factors for CKD progression and cardiovascular disease in children with CKD and has highlighted the effects of CKD on outcomes unique to children, including neurocognitive development and growth. This review summarizes findings to date, illustrating the spectrum of CKD-associated complications in children and emphasizing areas requiring further investigation. Taken in sum, these elements stress that initiating treatment at an early age is essential for reducing long term morbidity and mortality in children with CKD.

show abstract

Section: Cardiovascular Disease Risk Factors In Children With Ckdmentioning

confidence: 99%

CKiD (CKD in Children) Prospective Cohort Study: A Review of Current Findings

Wong

Moxey-Mims

Jerry-Fluker

et al. 2012

American Journal of Kidney Diseases

231

152

View full text Add to dashboard Cite

show abstract

“…The etiology of growth failure in CKD is multifactorial. While growth rates are loosely correlated with the overall degree of renal dysfunction (4), the individual degree of growth impairment is believed to reflect variable contributions of individual endocrine and metabolic complications of CKD including accumulation of inhibitors of growth hormone (GH) and insulin-like growth factor (IGF)-1 signaling, the malnutrition-inflammation complex, metabolic acidosis, renal anemia, and hyperparathyroidism (5).…”

Section: Introductionmentioning

confidence: 99%

Determinants of Statural Growth in European Children With Chronic Kidney Disease: Findings From the Cardiovascular Comorbidity in Children With Chronic Kidney Disease (4C) Study

Behnisch¹,

Kirchner²,

Anarat³

et al. 2019

Front. Pediatr.

Self Cite

View full text Add to dashboard Cite

Failure of statural growth is one of the major long-term sequelae of chronic kidney disease (CKD) in children. In recent years effective therapeutic strategies have become available that lead to evidence based practice recommendations. To assess the current growth performance of European children and adolescents with CKD, we analyzed a cohort of 594 patients from 12 European countries who were followed prospectively for up to 6 years in the 4C Study. While all patients were on conservative treatment with a mean estimated glomerular filtration rate of 28 ml/min/1.73 m 2 at study entry, 130 children commenced dialysis during the observation period. At time of enrolment the mean height standard deviation score (SDS) was −1.57; 36% of patients had a height below the third percentile. The prevalence of growth failure varied between countries from 7 to 44% Whereas patients on conservative treatment showed stable growth, height SDS gradually declined on those on dialysis. Parental height, pubertal status and treatment with recombinant growth hormone (GH) were positively, and the diagnosis of syndromic disease and CKD stage were negatively associated with height SDS during the observation period. Unexpectedly, higher body mass index (BMI) SDS was associated with lower height SDS both at enrolment and during follow up. Renal anemia, metabolic acidosis, and hyperparathyroidism were mostly mild and not predictive of growth rates by multivariable analysis. GH therapy was applied in only 15% of growth retarded patients with large variation between countries. When adjusting for all significant covariates listed above, the country of residence remained a highly significant predictor of overall growth performance. In conclusion, growth failure remains common in European children with CKD, despite improved general management of CKD complications. The widespread underutilization of GH, an approved efficacious therapy for CKD-associated growth failure, deserves further exploration.

show abstract

“…Two periods are at a particular risk of impaired growth velocity: infancy and puberty. Height velocity generally decreases once GFR is below 25 ml/min/1.73 m 2 [ 35 ]. However, there is evidence that growth impairment already starts earlier.…”

Section: Kidney Transplantationmentioning

confidence: 99%

Growth in children on kidney replacement therapy: a review of data from patient registries

et al. 2021

View full text Add to dashboard Cite

Growth retardation is a major complication in children with chronic kidney disease (CKD) and on kidney replacement therapy (KRT). Conversely, better growth in childhood CKD is associated with an improvement in several hard morbidity–mortality endpoints. Data from pediatric international registries has demonstrated that improvements in the overall conservative management of CKD, the search for optimal dialysis, and advances in immunosuppression and kidney transplant techniques have led to a significant improvement of final height over time. Infancy still remains a critical period for adequate linear growth, and the loss of stature during the first years of life influences final height. Preliminary new original data from the European Society for Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry confirm an association between the final height and the height attained at 2 years in children on KRT.

show abstract

Growth charts for prepubertal children with chronic renal failure due to congenital renal disorders

Cited by 65 publications

References 17 publications

CKiD (CKD in Children) Prospective Cohort Study: A Review of Current Findings

CKiD (CKD in Children) Prospective Cohort Study: A Review of Current Findings

Determinants of Statural Growth in European Children With Chronic Kidney Disease: Findings From the Cardiovascular Comorbidity in Children With Chronic Kidney Disease (4C) Study

Growth in children on kidney replacement therapy: a review of data from patient registries

Contact Info

Product

Resources

About